Eribulin Mesylate

A Novel Halichondrin B Analogue for the Treatment of Metastatic Breast Cancer

Ali McBride, Pharm.D., M.S., BCPS; Sara K. Butler, Pharm.D., BCPS, BCOP


Am J Health Syst Pharm. 2012;69(9):745-755. 

In This Article

Dosage and Administration

The dosage of eribulin mesylate recommended by the manufacturer is 1.4 mg/m2 on days 1 and 8 of a 21-day cycle, with dosage reductions recommended for hepatic impairment and moderate renal impairment and dosage modifications recommended in patients with myelosuppression or other grade 3 or 4 nonhematologic toxicities.[21] Eribulin has additional properties that may be advantageous in the clinical setting, such as a rapid infusion time when compared with other microtubule-targeted agents. Because eribulin is a water-soluble compound, it does not require the use of lipophilic vehicles that can cause hypersensitivity reactions in patients; thus, premedication with corticosteroids and histamines is not required.[21,32] Eribulin mesylate is administered intravenously undiluted over two to five minutes or diluted in 100 mL of 0.9% sodium chloride injection and should not be administered in any solutions containing dextrose. Undiluted or diluted eribulin may be stored in a syringe or i.v. bag, respectively, for up to 4 hours at room temperature or up to 24 hours under refrigeration.[21]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.